Levosimendan as a therapeutic strategy to prevent neuroinflammation after aneurysmal subarachnoid hemorrhage?

BACKGROUND: Poor patient outcomes after aneurysmal subarachnoid hemorrhage (SAH) occur due to a multifactorial process, mainly involving cerebral inflammation (CI), delayed cerebral vasospasm (DCVS), and delayed cerebral ischemia, followed by neurodegeneration. CI is mainly triggered by enhanced syn...

Descripción completa

Detalles Bibliográficos
Autores principales: Wanderer, Stefan, Andereggen, Lukas, Mrosek, Jan, Kashefiolasl, Sepide, Schubert, Gerrit Alexander, Marbacher, Serge, Konczalla, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Basic Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938656/
https://www.ncbi.nlm.nih.gov/pubmed/34039684
http://dx.doi.org/10.1136/neurintsurg-2021-017504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938656/
https://www.ncbi.nlm.nih.gov/pubmed/34039684
http://dx.doi.org/10.1136/neurintsurg-2021-017504

Ejemplares similares